DoD Amyotrophic Lateral Sclerosis Research Program

DoD Amyotrophic Lateral Sclerosis Research Program 
Therapeutic Development Award
Amount of funding: Direct costs budgeted will not exceed $1,000,000.
Purpose:  The FY20 ALSRP Therapeutic Development Award supports research ranging from validation
of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Preliminary data are required, including efficacy in at least one ALSrelevant model system with a lead molecule/class of compounds. Clinical trials are not allowed, however, validation of treatment approaches in appropriately powered and controlled studies using biological correlates of disease activity and progression in pre-existing, de-identified human specimens from well-characterized patient cohorts is encouraged. Biomarker development and/or characterization (if not already validated), in parallel to the main therapeutic effort, is a critical component of the FY20 ALSRP Therapeutic Development Award.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be the PI or a Partnering PI.
Not eligible: Instructors, Clinical Instructors, Academic staff-research (i.e., research associates), and postdocs are not eligible for this RFP because Stanford does not consider them to be independent positions.
Timeline:
Pre-application/Letter of intent (required) deadline:   April 15, 2020 via eBrap
Please include your RPM’s name as business official in the pre-application.
Institutional representative (RPM/RMG or CGO/OSR) deadline:   July 16, 2020
Full proposal deadline:  July 23, 2020 via grants.gov
Guidelines: https://cdmrp.army.mil/funding/alsrp

DoD Amyotrophic Lateral Sclerosis Research Program 
Therapeutic Idea Award
Amount of funding: Direct costs budgeted will not exceed $500,000.
Purpose:  The FY20 ALSRP Therapeutic Idea Award supports hypothesis-driven therapeutic development
and is designed to promote new ideas aimed at drug or treatment discovery that are still in the early stages of development. Development and/or modification of preclinical model systems or the application of high-throughput screens to define or assess lead compounds for ALS treatment may also be proposed. All research projects should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality. Preliminary data are not required. Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be PI. Early career investigators (defined as independent, non-mentored investigators within 5 years of their last training position e.g., postdoctoral fellowship, medical residency, clinical fellowship as of the application submission deadline) are encouraged to apply.
Not eligible: Instructors, Clinical Instructors, Academic staff-research (i.e., research associates), and postdocs are not eligible for this RFP because Stanford does not consider them to be independent positions.
Timeline:
Pre-application/Letter of intent (required) deadline:   April 15, 2020 via eBrap
Please include your RPM’s name as business official in the pre-application.
Institutional representative (RPM/RMG or CGO/OSR) deadline:   July 16, 2020
Full proposal deadline:  July 23, 2020 via grants.gov
Guidelines: https://cdmrp.army.mil/funding/alsrp

DoD Amyotrophic Lateral Sclerosis Research Program 
Therapeutic Development Award
Amount of funding: Direct costs budgeted will not exceed $300,000.
Purpose:  The intent of the FY20 ALSRP Clinical Development Award mechanism is to support studies
leveraging human-based ALS resources to enrich clinical trials, in addition to projects designed to optimize components of current ALS clinical care. Leveraging can refer to the use of existing well-characterized and highly curated resources, or collaboration with ongoing clinical research to amplify potential gains in knowledge.
Eligibility: Independent investigators - Faculty with PI eligibility and CE faculty (with an approved CE faculty PI waiver obtained through their RPM in RMG prior to the pre-application/letter of intent) may be PI. Early career investigators (defined as independent, non-mentored investigators within 5 years of their last training position e.g., postdoctoral fellowship, medical residency, clinical fellowship as of the application submission deadline) are encouraged to apply.
Not eligible: Instructors, Clinical Instructors, Academic staff-research (i.e., research associates), and postdocs are not eligible for this RFP because Stanford does not consider them to be independent positions.
Timeline:
Pre-application/Letter of intent (required) deadline:   April 15, 2020 via eBrap
Please include your RPM’s name as business official in the pre-application.
Institutional representative (RPM/RMG or CGO/OSR) deadline:   July 16, 2020
Full proposal deadline:  July 23, 2020 via grants.gov
Guidelines: https://cdmrp.army.mil/funding/alsrp

Please include your institutional official's name (RPM/RMG or CGO/OSR) as business official in the pre-application/LOI.

Review the General Application Instructions.